ABSTRACT. We studied ten normoglycemic [maternal glucose (GA) = 70 mg/dL] and six insulin-induced hypoglycemic (GA = 22 mg/dL) pregnant sheep to test the hypothesis that development of fetal glucose production (GPR) could help maintain fetal glucose concentration, limit uteroplacental-fetal glucose transfer (UPGT), and sustain uteroplacental glucose consumption (UPGC). Compared with the normoglycemic group, the hypoglycemic group demonstrated the following values: fetal glucose concentration (G,) was 9.8 + 0.8 mg/dL (51% lower, p < 0.01), uterine glucose uptake (UtGU) was 16.7 2 1.4 mg/min (54% lower, p < 0.01), UPGT was 3.1 + 0.6 mg/min (81% lower, p < 0.001), and UPGC was 13.6 2 1.4 mg/min (30% lower, p < 0.05). The reduction in UPGC was significantly less ( p < 0.05) than the reductions in UPGT and UtGU. Fetal glucose utilization rate (CUR) was decreased 20% ( p < 0.05) to 3.99 + 0.35 mg/min/kg. A further decrease in CUR was prevented by the appearance of fetal GPR of 2.82 + 0.32 mg/min/kg ( p < 0.05) compared with negligible GPR in the normoglycemic group. UPGT and UPGC in both groups were not influenced by maternal or fetal insulin infusions as long as G, did not change; however, fetal glucose infusion that increased G, increased UPGC in both groups. We conclude that, during chronic maternal hypoglycemia, increased fetal GPR limits the simultaneous decrease in fetal CUR and glucose concentration. By sustaining G, fetal GPR limits UPGT to a significantly greater extent than UtGU, diverting UtGU to UPGC. Thus, fetal GPR promotes placental as well as fetal metabolic autonomy when the maternal supply of glucose is reduced. (Pediatr Res 25:429-434, 1989) Abbreviations GPR, fetal glucose production GA, maternal glucose concentration G,, fetal glucose concentration GIR, glucose infusion rate UGU, umbilical glucose uptake rate (equal to UPGT) UPGT, uteroplacental-fetal glucose transfer UPGC, uteroplacental glucose consumption GUR, glucose utilization rate
fasted, pregnant sheep that, at rates of net fetal glucose uptake less than half of normal, fetal glucose utilization significantly exceeded umbilical glucose uptake (1, 2) . Similar preliminary studies showed the progressive development of a positive fetal hepatic vein-umbilical vein glucose concentration difference after three d of fasting-induced maternal and fetal hypoglycemia (3) . We interpreted these observations as evidence of GPR by the fetus itself. As previous studies (4, 5) found negligible rates of fetal GPR during maternal normal glycemia, an increased fetal GPR presumably serves to maintain the rate of fetal glucose utilization when maternal glucose supply decreases. It is not obvious, however, how fetal GPR might also affect placental glucose flux. This is an important concern because in recent experiments using fetal glucose and insulin infusions we observed that changes in fetal glucose concentration significantly altered UPGT and UPGC independent of fetal insulin concentration, maternal glucose concentration, and maternal glucose supply to the placenta (6) . These observations suggested that fetal GPR could regulate placental glucose flux via effects on fetal glucose concentration. This mechanism would provide relative autonomy of fetal and placental metabolism at times when maternal glucose supply is limited.
To test this hypothesis, we infused insulin into pregnant sheep during the last 20% of gestation, producing periods of up to 3 wk of maternal hypoglycemia. During these periods, fetal and placental glucose metabolism were studied using combined Fick principle, glucose clamp, and tracer techniques. The present report documents the development of fetal GPR at low levels of maternal glucose concentration and maternal glucose supply to the fetus and describes how fetal GPR affects placental glucose transfer and consumption independent of maternal regulation.
MATERIALS AND METHODS
Animal preparation. Experiments were conducted in pregnant Columbia-Rambouillet ewes, each carrying a single fetus. The ewes were fasted for two days prior to surgery. Surgery was performed at approximately 1 15 d of gestation under intravenous pentobarbital sedation (5.0 mg/kg) and pontocaine spinal anesthesia (6.0 mg in hypertonic glucose). Maternal catheters for infusion were placed into a femoral vein through a groin incision. Maternal catheters for sampling included a femoral artery catheter (placed via the groin incision), and after a midline laparotomy was performed, a uterine venous catheter was placed into the main uterine vein draining the pregnant uterine horn containing the study fetus. A standard hysterotomy was performed, and catheters for fetal infusions were placed into fetal femoral veins via hindlimb pedal veins. Additional catheters for fetal blood sampling were placed in the fetal abdominal aorta via a hindlimb pedal artery and into the common umbilical vein. All catheters were tunneled subcutaneously through a flank incision on the ewe and kept within a plastic pouch attached to the ewe's skin. The catheters were flushed every other d with heparinized 0.9% wt/vol sodium chloride (30 U heparin/mL 0.9% sodium chloride). Each ewe was allowed to recover postoperatively for 2-3 d until behavior, food intake, and water intake were normal. The ewes were kept in carts and given an ad libitum diet of alfalfa pellets, water, and mineral supplements. They were kept in a room with the temperature controlled between 10 and 20°C. At least two sheep were always kept together for company.
Study design. One group of 10 ewes was used for control studies and did not receive any intravenous infusions except at the time of study. Arterial blood was sampled daily for maternal and fetal glucose concentrations. A second group of six ewes received a continuous infusion of insulin intravenously for approximately 3 wk. During this time, maternal arterial and fetal arterial blood were sampled once or twice daily for measurement of glucose and insulin concentrations with subsequent adjustment of the insulin infusion rate to achieve a desired maternal arterial blood glucose concentration of approximately 20-25 mg/ dL, an estimated reduction of 50% from normal. Studies were conducted in each ewe at least 2 wk after establishing the desired level of maternal arterial glucose concentration. At the start of each study, a continuous infusion of antipyrine (10% wt/vol in normal saline, approximately 3.0 mg/ min/kg) was given to each fetus via a saphenous vein catheter to measure umbilical and uterine blood flow. At the same time, each fetus received a primed, constant infusion of [U-14C]glucose (-40 &/kg estimated fetal wt followed by -0.4 pCi/min/kg) to measure fetal glucose utilization rate (5) . Blood samples were drawn from the uterine vein, maternal artery, fetal aorta, and common umbilical vein simultaneously at 90, 100, 110, and 120 min of the study. Whole blood samples for blood glucose, I4C-glucose, and antipyrine and for plasma insulin concentrations were drawn into plastic syringes lined with EDTA. Plasma for insulin assay was separated in a refrigerated centrifuge and stored at -70°C until time of assay. Whole blood samples for oxygen content analysis were drawn into glass capillaries lined with dried sodium heparin and sodium fluoride.
After the control period, two different fetal clamp studies were performed in both control and hypoglycemic animals on separate days. These studies were performed at least 2 d apart in random sequence. For the euglycemic-hyperinsulinemic clamp, insulin (pure pork insulin, Eli Lilly Corp., Indianapolis, IN, diluted in 30 mL 0.9% wt/vol sodium chloride and 7 mL maternal sheep plasma) was infused into each fetus via a saphenous vein catheter at approximately 1.0 mU/min/kg estimated fetal wt after a prime dose of 40 mU/kg. At 10 min after the insulin infusion was started, dextrose infusion (10% wt/vol in water, Travenol Laboratories, Inc., Deerfield, IL) was added, starting at 2.5 mg/min/ kg estimated fetal wt. Fetal arterial blood glucose concentration was then sampled at 10-min intervals, and the dextrose infusion rate was adjusted to maintain the mean fetal arterial blood glucose concentration of the control period. The adjustment in fetal GIR was made according to the following algorithm (7, 8) :
where Gd is the desired fetal arterial blood glucose concentration (mg/dL), Gi is the glucose concentration at any time "i,", 4 is the estimated fetal glucose space (dL/kg), wt is the estimated fetal wt (kg) at study, and 10 min converts the pool correction factor in brackets to a rate change over ten min. Blood samples identical to the control period were obtained at 120, 130, 140, and 150 min after the start of the insulin infusion.
For the hyperglycemic clamp, no insulin infusion was used. Fetuses received a dextrose infusion as described above, with the exception that the infusion rate was adjusted to maintain the fetal arterial blood glucose concentration at approximately 40 mg/dL (-2 times control) in group 1 fetuses and at approximately 20 mg/dL (-"normal" glucose concentration) in group 2 fetuses. Fetal insulin concentration was not clamped. Therefore, insulin concentration could change in response to the change in glucose concentration. Samples identical to those drawn during the control period were obtained at 100, 1 10, 120, and 130 min after starting the dextrose infusion. Fetal blood samples were replaced by equal vol of maternal blood immediately after sampling.
At the end of the study, the ewe and fetus were killed with a rapid intravenous infusion of T-6 1 euthanasia solution (Taylor Pharmaceutical Co., Decatur, IL). An autopsy was performed to obtain fetal wt and placental cotyledonary number and wt. The study was approved by the University of Colorado Health Sciences Center Institutional Animal Care and Use Committee.
Chemical and analytical methods. Whole blood glucose concentration was measured by a glucose oxidase method (Sigma Chemical Co., St. Louis, MO). Whole blood [14C]glucose was measured using an ion exchange chromatography method (5) . Whole blood antipyrine concentration was measured by a Technicon Autoanalyzer according to the method described by Meschia et al. (9) and Wilkening et al. (10 (9, 10) . Net glucose and oxygen uptakes by the uterus, the fetus (equal to the net transfer from uteroplacenta to fetus), and the uteroplacenta (equal to net uteroplacental consumption) were calculated by the Fick principle as previously described (1). Fetal glucose utilization rate was calculated as the net fetal ['4C]glucose uptake rate divided by fetal arterial blood glucose sp act (5). Net fetal GPR was calculated as the difference between fetal glucose utilization rate and net fetal glucose uptake by the umbilical circulation in the control period or total glucose entry (UGU + GIR) in the insulinglucose clamp periods (4). These calculations used the mean blood flow and mean arteriovenous substrate concentration differences of the four blood samples during the 30 min of each study period. Fetal wt at the time of study was estimated using the formula (8):
Plasma glucose concentrations were calculated from the measured whole blood glucose concentrations using the following formulas:
for maternal values:
for fetal values:
where P is concentration of glucose in plasma (mg/dL), W is whole blood glucose concentration (mg/dL), and H is hematocrit expressed as a fraction (1 1 were not different when calculated on a wt-specific basis (fetal wt for fetal oxygen uptake, fetal plus placental cotyledonary wt for uterine oxygen uptake). Uteroplacental oxygen consumption rates were not different between the two groups overall or per g of placental wt. Net oxygen uptake rates by the uterus, fetus, and uteroplacenta did not change significantly during the hyperinsulinemic-euglycemic insulin clamp or the hyperglycemic glucose clamp. Glucose fluxes are presented in Table 3 and Figure 2 . Control period uterine glucose uptake was reduced by 54.0% in group 2. Fetal glucose uptakes were reduced by 75.7% and net uteroplacental glucose uptake (consumption) was reduced by 30.6%.
Fetal glucose utilization rate was 19.6% lower in group 2 ( p < 0.05) compared with group 1. Calculated fetal GPR increased from the negligible value in group 1 to nearly 3.0 mg/min/kg in group 3 (GPR different from 0, p < O.Ol), accounting for 70.7% of fetal GUR.
During the euglycemic hyperinsulinemic clamps in each group there were no significant changes from the control period in maternal and fetal arterial plasma glucose concentrations or net uterine, fetal, and uteroplacental glucose uptake rates. During the hyperglycemic fetal glucose clamps in group 1, maternal glucose concentration did not change significantly, but uterine uptake was reduced by 37% ( p < 0.01) from the control period. Uteroplacental glucose consumption increased by 6 1 % ( p < 0.0 l), equal to the sum of the uterine glucose uptake and the net glucose flux from fetus to placenta. Fetal GUR increased 3 1.2% ( p < 0.05) from the euglycemic, insulin clamp period and 8 1.3% ( p < 0.01) from the control period. During the hyperglycemic glucose clamps in group 2 animals, there was no change in maternal arterial plasma glucose concentration or uterine glucose uptake. UPGC increased 78.0% ( p < 0.01) above the control period and 89.5% ( p < 0.01) above the euglycemic, insulin infusion period. Fetal glucose concentration was slightly (14.6%) but significantly ( p < 0.05) higher than that of the control period mean value in the group 1 animals, as was the uteroplacental glucose consumption (23.6%, p < 0.05). The latter was accounted for by the sustained uterine glucose uptake and the negative umbilical glucose uptake. Fetal GUR increased 46.0% ( p < .001) from the euglycemic, insulin clamp period and 80.7% ( p < 0.01) from the control period.
Uteroplacental glucose consumption averaged 53.8% of net uterine glucose uptake in group 1 in the control period and 8 1.3% in group 2 ( p < 0.01). These proportions were not changed during the euglycemic clamps, but hyperglycemia in the fetuses in both groups increased UPGC to 100% of net uterine uptake: 72.9% from the maternal circulation, 27.1% from the fetus in group 1; 66.5% from the maternal circulation, 33.5% from the fetus in group 2. These proportions were not significantly different between groups.
DISCUSSION
In the present study, sustained maternal hyperinsulinemia in pregnant sheep significantly reduced maternal arterial glucose concentration, the uptake of glucose by the uterus, the net consumption of glucose by the uteroplacenta, the transfer of glucose to the fetus, fetal glucose and insulin concentrations, and fetal glucose utilization rate. The reductions in maternal glucose concentration and uterine glucose uptake were disproportionately greater than the other glucose decreases. The reason for these discrepancies appears to be the development of GPR by the fetus itself, which sustained fetal glucose concentration and fetal glucose utilization by the addition of glucose molecules to the fetal glucose pool. The relative increase in fetal glucose concentration also reduced the maternal-fetal arterial glucose gradient to a greater extent than that produced by the fall in maternal glucose concentration. Consequently, net glucose transfer to the fetus (measured as net umbilical glucose uptake) was reduced by a larger fraction than the uterine glucose uptake, providing more glucose for uteroplacental consumption. The measured decrease in placental transport of glucose to the fetus and the increase in net uteroplacental glucose consumption represent, therefore, unique demonstrations that fetal GPR can contribute to maintenance of fetal glucose concentration (and 
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Fetal Fetal ~e t a l ' F e t a l Euglycemic Hyperglycemic Euglycemic Hyperglycemic C l a m p C l a m p C l a m p C l a m p Fig. 2 . Glucose flux rates in the normoglycemic, group 1 animals (lefi) and the hypoglycemic, group 2 animals (right) during control ( l o p ) and euglycemic and hyperglycemic fetal clamp (bottom) periods. Net fetal glucose entry is equal to net UGU in the control periods and to UGU plus GIR in the clamp periods.
the maternal-fetal glucose gradient) and thus regulate the exchange of glucose between placenta and fetus as well as the consumption of glucose by the uteroplacental tissues.
Our previous study (6) using glucose infusions to alter fetal glucose concentrations also demonstrated that fetal glucose concentration affected uteroplacental glucose consumption. At physiologic concentrations we showed that UPGC was directly related to Ga. This effect was independent of maternal glucose concentration and uterine glucose supply from the uterine circulation. It appears from the present study that an increase in G, relative to GA affects the distribution of glucose molecules entering the uteroplacenta by reducing the transfer of glucose to the fetus, thus increasing the availability of glucose for placental consumption. Under these conditions, fetal glucose concentration contributes independently to the net determination of the intratrophoblast glucose supply and most likely the intratrophoblast glucose concentration, both of which appear to have direct effects on uteroplacental glucose consumption. The effect of the intratrophoblast glucose supply on UPGC has been suggested previously in studies by Crandell et a/. (12) as well as investigations in our laboratory (13) in which G, and GA were increased by a maternal glucose infusion that increased intratrophoblast glucose supply.
Although the present study is unique in its demonstration of the role of fetal GPR in regulation of fetal glucose concentration, earlier investigators have suggested that placental glucose flux is controlled to some degree by G,. In 1952, Widdas ( 14) proposed that the placental transfer of glucose to the fetus was dependent on a complex function of the maternal-fetal arterial plasma glucose gradient:
Simmons et a/. (15) provided a unique set of experimental data in pregnant sheep which supported the validity of this equation but also demonstrated that the expression had a negative yintercept; that is, as G, approached GA, UPGT was reduced to 0, then ultimately reversed direction such that net glucose transfer was from fetus to uteroplacenta. Thus,
where -q, is the net rate of glucose transferred from fetus to placenta when G, = GA. In these studies, GA and G, were regulated by the infusion of glucose into the mother and/or the fetus. More recently, we studied UPGT at several maternal-fetal glucose gradients established by fixing GA and infusing dextrose into the fetus to produce discrete steady-state glucose concentrations in the physiologic range. These studies demonstrated an inverse relationship between G, and UPGT (6) . Together these earlier observations provided evidence defining the specific role of fetal glucose concentration in determining the maternal-fetal glucose gradient and thereby regulating the net transfer of glucose from the uterine to the umbilical circulation by the placenta. The data in the present study confirm the effect of G, on UPGT. Furthermore, they uniquely demonstrate that this interaction is regulated by fetal physiologic mechanisms and is not a phenomenon seen only during experimental manipulation with exogenous fetal glucose and insulin infusions.
In addition to the effects on G,, UPGT, and UPGC, fetal GPR also provided glucose to sustain fetal glucose utilization rate. In the hypoglycemic group, UPGT was only 19% of the value in the control group; at the same time fetal C U R was 80% of the control value. This relatively high level of C U R during hypoglycemia exceeds by 1.5-fold the value estimated from our previous study of the effect of G, and I, on fetal C U R (4). In that study, fetal GPR was not present. Thus, fetal GPR serves three purposes: I ) it provides glucose molecules to sustain fetal glucose concentration when maternal glucose supply decreases markedly; 2) by maintaining G,, it reduces the placental transfer of glucose to the fetus, making maternal glucose more available for placental consumption; and 3) it provides glucose molecules for fetal glucose utilization. All of these effects have been demonstrated using an exogenous infusion of glucose into the fetus (4). In the present study, similar effects were produced by physiologic cha~lges in fetal metabolism. The end result is that, in the presence of a reduced supply of glucose from the mother, the fetus has the capacity to become more autonomous, reducing the demand on maternal glucose supply while continuing to meet the glucose needs of itself and its essential supply organ, the placenta. The absence of any significant change in oxygen supply suggests that the development of fetal GPR is a response to reduced glucose supply and not to oxygen deficit, an observation in keeping with the idea that the fetus can vary its rates of substrate metabolism in response to selective nutritional deprivation while maintaining normal rates of oxidative metabolism. The specific changes in substrate metabolism have not been documented experimentally. However, it is likely that during severe maternal hypoglycemia fetal amino acid metabolism is altered, increasing the availability of the glucogenic amino acids (e.g. alanine) for gluconeogenesis. Studies of leucine metabolism in fetal lambs after fasting-induced maternal and fetal hypoglycemia suggest that increased amino acid availability is due to increased protein degradation rather than decreased protein synthesis (16) . This finding is supported further by studies of overall protein turnover in fetal rats during maternal starvation, which similarly found no change in the rate of protein synthesis but an increase in the rate of protein degradation (1 7).
Although several studies (4, 6, 18) have demonstrated convincingly the absence of any effect of maternal or fetal insulin concentration on placental glucose uptake, transfer, or consumption, one group has published data recently from which they drew a contradictory conclusion. During fetal insulin infusion under nonsteady-state conditions of maternal and fetal glucose concentration and placental glucose flux, Bloch et a/. (19) reported an apparent increase in the net extraction of tracer glucose from the umbilical circulation by the placenta. They suggested that this finding could be due to an insulin effect on placental glucose uptake. Therefore, in the present study a euglycemic. REFERENCES hyperinsulinemic insulin clamp was performed-in both control and hypoglycemic fetuses to assess possible effects of insulin on placental metabolism under steady-state conditions. In both cases, fetal arterial glucose concentration was maintained with tight precision at the control period mean glucose concentration. There was no change in placental-fetal glucose exchange in response to the hyperinsulinemia, and the tracer glucose distribution was increased into the fetus and away from the uteroplacenta in all cases. Thus, as in our previous studies, there is no effect of relative fetal hyperinsulinemia in placental flux of either tracer or unlabeled glucose. Only a change in fetal glucose concentration relative to the maternal glucose concentration has an effect on placental-fetal glucose exchange. This conclusion is further supported by the glucose infusion period in the normal and the hypoglycemic fetuses. In this situation, the increase in fetal glucose concentration relative to the maternal glucose concentration suppressed UPGT to the fetus and, in fact, reversed the flux to a net fetal-to-placental transfer. UPGC was increased at the same time even though the uterine glucose supply was unaffected.
During the hyperinsulinemic euglycemic clamp studies in group 2, G, and umbilical glucose uptake remained at control values. Therefore, the hypoglycemic stimulus to fetal GPR still existed concomitantly with hyperinsulinemia, which should have maintained a suppressive effect on glucogenesis. Under these conditions the calculated GPR was suppressed to a value not significantly different from 0. In addition, the insulin-enhanced GUR was accounted for by the rate of fetal intravenous glucose infusion. Thus, the hyperinsulinemic clamp experiments added further confirmation that the calculated GPR, although an indirect measurement, was valid.
In conclusion, the results of the present study demonstrate the development of fetal GPR in response to maternal hypoglycemia, fetal hypoglycemia, and a reduced placental transfer of glucose to the fetus. The fetal GPR helps to maintain fetal glucose concentration and fetal glucose utilization rate. The relatively maintained fetal glucose concentration in turn maintains a lower maternal-fetal glucose gradient, limiting UPGT to the fetus and diverting uterine glucose uptake to uteroplacental glucose consumption. Thus, fetal GPR provides an autonomous means by which the fetus sustains fetal and placental oxidative metabolism and glucose utilization in the presence of a reduced supply of glucose from the mother.
